MedTrace Logo

COVID-19: A Study to Evaluate Safety, Reactogenicity and Immunogenicity of the SARS-CoV-2 mRNA Vaccine CVnCoV in Adults With Co-morbidities

NCT04860258 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 129

Last updated 2022-05-13

Study results available
· View outcomes & findings →

Summary

The primary objectives of this study are to evaluate the safety and reactogenicity profile after 1 and 2 dose administrations of investigational SARS-CoV-2 mRNA vaccine CVnCoV, and to evaluate the humoral immune responses 14 days after 2 dose administrations of CVnCoV.

Conditions

  • Coronavirus
  • Covid19
  • SARS-CoV-2
  • Severe Acute Respiratory Syndrome

Interventions

BIOLOGICAL

CVnCoV Vaccine

Intramuscular (IM) injection in the deltoid area, preferably in the non-dominant arm.

Sponsors & Collaborators

  • CureVac

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-22
Primary Completion
2021-09-21
Completion
2021-09-21

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04860258 on ClinicalTrials.gov